The MicroFlow Spacer: A Drug-Eluting Stent for the Ethmoid Sinus

Area of Science:

• Otolaryngology
• Rhinology
• Medical Device Technology

Background:

• Chronic rhinosinusitis (CRS) significantly impacts quality of life.
• Medically refractory CRS often requires surgical intervention.
• Ethmoid sinus surgery is a common treatment, but recurrence and complications can occur.

Purpose of the Study:

• To evaluate the short-term safety and efficacy of a novel drug-eluting ethmoid stent.
• To assess the impact of the triamcinolone-infused stent on patient-reported outcomes and radiographic scores.
• To compare outcomes with conventional endoscopic ethmoidectomy.

Main Methods:

• Prospective study involving 23 patients with medically refractory CRS.
• Ethmoid sinuses treated with triamcinolone-infused stents instead of traditional ethmoidectomy.
• Outcomes assessed using Sino-Nasal Outcome Test (SNOT-20) and Lund-MacKay CT scores over 6 months.
• Safety evaluated through intra-operative and post-operative adverse events.

Main Results:

• Significant improvement in SNOT-20 scores (1.16 reduction, P < 0.001).
• Statistically significant reduction in ethmoid-specific Lund-MacKay scores (0.83, P < 0.001).
• Significant improvement in side-specific Lund-MacKay scores (2.80 reduction, P < 0.001).
• No significant intra-operative or post-operative complications were reported.

Conclusions:

• The triamcinolone-infused ethmoid stent is safe and effective for chronic ethmoid sinus disease within the 6-month follow-up.
• Direct medication delivery to diseased mucosa shows promise for managing CRS.
• This approach may offer a valuable alternative to conventional endoscopic ethmoidectomy.